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Objective: To investigate whether the use of beta-blockers (b-blockers) in patients with idiopathic
hypertension compromises exercise performance.
Materials and Methods: Retrospectively, patients with well-controlled hypertension, who had received
cardiopulmonary exercise testing (CPET) and pulmonary function testing, were consecutively enrolled.
Their medical histories were reviewed. They were grouped into those receiving b-blockers and those
receiving other antihypertensives. The heart rate (HR), blood pressure, oxygen consumption ( _VO2),
oxygen pulse, ventilatory anaerobic threshold, and respiratory exchange ratio were measured during
CPET. The forced vital capacity and forced expiratory volume in 1 second were also collected from
pulmonary function testing. Peak values of the CPET indices were compared between the two groups for
each index separately by the Mann-Whitney U test. A p value less than 0.05 was considered statistically
signiﬁcant.
Results: No signiﬁcant differences were observed in basic characteristics, such as age (59 9 years vs.
62 9 years), and peak oxygen pulse (11 3 vs. 11 4), between the groups receiving b-blockers and
other antihypertensives, respectively. Their resting systolic pressures were well controlled under anti-
hypertensive medication (114 13 mmHg vs. 118 19 mmHg). A signiﬁcantly lower maximal HR and
maximal systolic blood pressure during peak exercise was observed in the b-blocker group compared
with those in the other group (129.5 17.0 beats/min vs. 146.1 18.3 beats/min, p¼ 0.008, and
159.0 22.2 mmHg vs. 172.6 29.8 mmHg, p¼ 0.028, respectively). The exercise capacity of the b-
blocker group was reduced, as shown by a lower measured peak _VO2/predicted peak _VO2 ( _VO2%)
(84.2% 9.6% vs. 96.2% 14.6%, p¼ 0.003) and a higher exercise heart rate reserve percentage
(19.8% 10.3% vs. 7.8 10.3%, p¼ 0.001).
Conclusions: The maximal HR, systolic blood pressure during peak exercise, and _VO2% were lower,
whereas the exercise heart rate reserve percentage was greater in patients treated with b-blockers than
in those taking other antihypertensives.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Hypertension is one of the most important independent risk
factors of cardiovascular disease. Patients with a blood pressure
(BP) greater than 110/75 mmHg have been shown to have increased
risks of mortality and morbidity [1]. The most widely usededicine and Rehabilitation,
Chung-Yang Road, Hualien,
7161.
.
ddhist Compassion Relief Tzu Chiantihypertensive agents are beta-blockers (b-blockers), thiazide
diuretics, calcium channel blockers (CCB), angiotensin-converting
enzyme inhibitors (ACEIs), and angiotensin II receptor antagonists
(ARBs). b-Blockers are only recommended for the initial treatment
of heart failure, a history of coronary heart disease, or a hyper-
adrenergic state [2]. Regular aerobic exercise of moderate intensity
can not only lower mean systolic BP (SBP) by 6.9 mmHg and mean
diastolic BP by 4.9 mmHg [3,4], but also achieve weight loss,
enhance the sense of well-being, improve functional health status,
and reduce the risk of cardiovascular disease [5]. b-Blockers are
supposed to diminish myocardial contractibility and attenuate the
heart rate (HR) responses to dynamic exercise. Prior studies [6e8]Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics
Characteristics b-Blockers Other
antihypertensive
regimen
p
n (%) (female) 22 (59) 23 (52)
Age (y) 58.6 9.4 61.9 9.4 0.111
Height (cm) 160.8 8.6 162.4 7.9 0.467
Weight (kg) 70.5 14.3 70.3 11.3 0.811
Body mass index (kg/m2) 27.1 4.3 26.6 3.2 0.856
Predicted _VO2 (mL/min) 1653.5 447.5 1625.2 455.2 0.699
Maximal exercise ventilation (L) 50.1 16.9 58.1 15.7 0.066
Systolic blood pressure
at rest (mmHg)
114.6 13.3 118 19.4 0.768
FEV1 (%) 95.8 14.4 90.2 13.4 0.168
FVC (%) 94.8 13.3 93.6 14.6 0.793
FEV1/FVC (%) 86.5 10.0 88.4 15.9 0.952
Data are expressed as n (% of female) or mean standard deviation.
FEV1¼ forced expiratory volume in 1 second; FVC¼ forced vital capacity.
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alpha-blockers, ACEIs) on exercise performance in physically active
or general hypertensive populations. Most studies revealed that
patients on b-blockers achieved a lower maximal HR and maximal
SBP. The maximal work rate and maximal oxygen consumption
( _VO2max) were signiﬁcantly lower in patients on b-blockers than
those taking ACEIs. However, in clinical treatment, combination
therapy is often needed for adequate control of BP. The aim of this
study was to compare whether the use of b-blockers in addition
to other antihypertensive regimens during exercise inﬂuences
_VO2max, the BP response, and exercise capacity in sedentary patients
with idiopathic hypertension.
2. Materials and methods
2.1. Participants
Participants were recruited retrospectively from another study
“Cardiopulmonary Exercise Testing (CPET) in Patients with
Preclinical Diastolic Ventricular Dysfunction.” From March 2010 to
April 2011, patients with idiopathic hypertension, 45e70 years old,
under regular antihypertensive treatment, with a well-controlled
BP, deﬁned as an SBP less than 140 mmHg and a diastolic pressure
less than 90 mmHg for more than 1 month, were enrolled
consecutively. All patients received CPET and pulmonary function
testing.
Patients were excluded from the study if they had (1) clinical
evidence of respiratory disease, including chronic obstructive
pulmonary disease, cor pulmonale, parenchymal lung disease, or
restrictive lung disease; (2) signiﬁcant valvular heart disease,
arrhythmia, or history of any thoracic surgery; (3) congenital
anomalies; (4) recent history of symptomatic myocardial ischemia
or exercise-induced myocardial ischemia; (5) anemia
(hemoglobin< 10 g/dL); (6) inability to exercise on a cycle
ergometer for other reasons (e.g., neurologic or orthopedic
diseases); (7) a disease that made exercise risky, for example,
suspicion of aortic dissection, aortic aneurysm, cerebral artery
aneurysm, deep vein thrombosis, exercise-induced asthma,
hyperthyroidism, or history of syncope; or (8) an insufﬁcient
ventricular ejection (<50%) proven by echocardiography or
a myocardial nuclear scan. Patients were divided into two groups:
those who used b-blockers and those who used other antihyper-
tensives, including thiazide diuretics, CCBs, ACEIs, and ARBs.
2.2. Cardiopulmonary exercise testing
CPET was performed with a cycle ergometer (MasterScreen CPX;
Cardinal Health, Germany 234 GmbH, Hoechberg). Gas exchange
(breath by breath), ventilation, electrocardiography, BP, and oxyhe-
moglobin saturation by pulse oximetry were recorded during the
entire exercise test, which included resting for 3 minutes, unloaded
pedaling at a cycling speed of 60 rpm for 3 minutes, an incremental
exercise test to symptom-limited maximum, and then a recovery
phase for 3 minutes. The work rate increment per minute was
estimated according to Wasserman et al’s formula [9] in an attempt
to keep the total incremental exercise time to about 10 minutes.
The indications for terminating exercise testing were (1) a fall in
SBP or mean BP greater than 10 mmHg; (2) development of
a signiﬁcant arrhythmia; (3) EKG readings of an ST segment
depression of 3 mm or greater; or (4) inability to maintain a cycling
frequency greater than 40 rpm.
The measured data in the testing included (1) the electrocar-
diogram and HR; (2) BP at baseline and during each exercise step;
(3) ventilatory gas exchange; (4) oxygen pulse (O2P¼ _VO2/HR); (5)
ventilatory anaerobic threshold, deﬁned as the _VO2 (mL/min) at thetime the respiratory exchange ratio¼ 1; (6) _VO2max, which was the
highest oxygen uptake achieved; and (7) the maximal exercise
ventilation. The percent of predicted oxygen consumption ( _VO2%) is
used to compare the tested peak _VO2 in healthy sedentary indi-
viduals. The calculation of the predicted peak _VO2 for healthy
sedentary men or womenwas done according toWasserman et al’s
formula [9]. The HR reserve (HRR) was estimated by the predicted
maximal HR (calculated by 220 e age) minus the maximal HR
during peak exercise. We calculated the exercise heart rate reserve
percentage (ExHRR%) as the percentage of HRR divided by the
predicted maximal HR.
2.3. Pulmonary function testing
Pulmonary function testing was conducted by a trained thera-
pist. We collected the forced vital capacity (FVC) and forced expi-
ratory volume in 1 second (FEV1) at rest before exercise and the
maximal voluntary ventilation. Other spirometry data were
collected according to American Thoracic Society standards.
2.4. Statistical analysis
Continuous variables are presented as mean standard devia-
tion. The Mann-Whitney U test was used to compare the two
groups for each index separately. A p value less than 0.05 was
considered statistically signiﬁcant. All statistical analyses were
performed with SPSS (version 18.0; SPSS Inc., Chicago, IL, USA). We
used the software, Power and Sample Size Calculations version
3.0.43 to examine the power of our study.
3. Results
A total of 45 patients were recruited in this study and were
divided into two groups: those taking b-blockers and those taking
other antihypertensives. The basic characteristics and medications
used by the patients during the study are listed in Tables 1 and 2.
Twenty-six patients were treated with a single agent (eight
received b-blockers only), 11 patients received two antihyperten-
sive medications, and eight patients had three medications. In both
groups, ARBs and diuretics were the most-often-combined medi-
cations, whereas ACEIs were less prescribed.
The mean age of the b-blocker group was 58.6 9.4 years
(n¼ 22), and the other group was 61.9 9.4 years (n¼ 23). Patients
were overweight (bodymass index> 24 kg/m2) in both groups. The
mean predicted _VO2 values in the two groups were almost the same
(1653.5 447.5 mL/min vs. 1625.2 455.2 mL/min, respectively,
p¼ 0.699). The mean SBP values at rest were normal and
Table 2
Patient medications
Type b-Blockers Other antihypertensive
regimen
b-Blockers 22 (100) 0
Angiotensin II receptor antagonists 9 (41) 15 (65)
Angiotensin-converting enzyme inhibitors 3 (14) 2 (9)
Diuretics 9 (41) 15 (65)
Calcium channel blockers 5 (23) 6 (26)
Data are presented as number (percent of total).
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118 19.4 mmHg, respectively), which may indicate similar effects
in control of hypertension under current medication. The param-
eters for pulmonary function testing, such as the maximal exercise
ventilation, FEV1%, FVC%, and the percent of FEV1/FVC, revealed no
other intrinsic factor that would interfere with exercise capacity in
our participants.
The mean _VO2max values in the two groups were similar
(1371.5 314.1 mL/min vs. 1578.9 544.5 mL/min, p¼ 0.34). The
mean achieved _VO2% was signiﬁcantly lower in the b-blocker group
than that in the other group (84.2% 9.6% vs. 96.2% 14.6%,
p¼ 0.003). There were also signiﬁcant differences in the mean HR
and SBP during peak exercise (129.517.0 beats/min vs.
146.118.3 beats/min, p¼ 0.008, and 159.0 22.2 mmHg vs.
172.6 29.8 mmHg, p¼ 0.028, respectively) between the two
groups. Patients carried out about the same workload during peak
exercise (102.0 31.9 W vs. 120 49.6 W, p¼ 0.269). The ExHRR%
was greater in the b-blocker group than that in the other group
(19.8% 10.3% vs. 7.8% 10.3%, respectively, p¼ 0.001). There were
no signiﬁcant differences in breathing reserve or peak O2P (Table 3).
4. Discussion
The present study demonstrated that hypertensive patients
treated with b-blockers presented with a lower HR, SBP, and _VO2%
during maximal exercise, but a greater ExHRR% than those taking
other antihypertensives.
The HRmax of the b-blocker group was signiﬁcantly lower,
whereas the ExHRR% was greater than that of the other group.
Cardiac output (CO) is a product of the HR and stroke volume. At low
exercise intensities, CO increases chieﬂy because of an increased
stroke volume, but at higher intensity levels, it increases mainly
because of an increased HR. The relationship of exercise intensity
with CO is essentially linear [10]. Fahrenbach et al compared the
effects of atenolol and doxazosin on physically active, hypertensive
men and noted that atenolol reduced HR and CO at rest and during
exercise and increased arteriovenous oxygen difference [6]. In our
study, there was no signiﬁcant difference in the peak O2P between
the two groups. We would be able to reject the null hypothesisTable 3
Cardiopulmonary exercise testing parameters
CPET parameters b-Blockers Other
antihypertensive
regimen
p
_VO2max (mL/min) 1371.5 314.1 1578.9 544.5 0.34
_VO2 (%) 84.2 9.6 96.2 14.6 0.003*
Peak systolic blood
pressure (mmHg)
159.0 22.2 172.6 29.8 0.028*
Maximal heart rate (beats/min) 129.5 17.0 146.1 18.3 0.008*
Peak O2 pulse (mL/beat/min) 10.9 2.9 11.1 3.8 0.776
Breathing reserve (L) 41.9 17.3 34.3 19.6 0.173
Exercise heart rate
reserve percentage (%)
19.8 10.3 7.8 10.3 0.001*
Maximal work rate (W) 102.0 31.9 120 49.6 0.269
*p< 0.05.that the peak O2P in the b-blocker and other antihypertensives
groups were equal with a probability (power) of 0.054. The use of
b-blockers leads to a lower HRmax and greater ExHRR% than that
of other antihypertensives, which would, in turn, limit the potential
of patients to perform at higher exercise intensities.
The maximal SBP during peak exercise was also lower in the b-
blocker users, which was compatible with those of previous studies.
Brion et al studied the exercise capacity of 96 physically active
hypertensive patients treated with bisoprolol and nitrendipine for
12 weeks [7]. The antihypertensive activity of bisoprolol on peak
exercise SBP was signiﬁcantly greater than that of nitrendipine.
Although there was no signiﬁcant difference in _VO2max in our
study, the _VO2% was signiﬁcantly lower in the b-blocker group (84%
vs. 96%). The predicted _VO2 was almost the same in the two groups,
and the lower _VO2max in the b-blocker group led to a lower _VO2%,
which was statistically signiﬁcant. Because the _VO2max could be
viewed as the aerobic capacity, we could predict that patients
treated with b-blockers would be unable to tolerate prolonged
exercise. The present study reported that when a b-blocker was
used during prolonged exercise, it lowered the HR, BP, and CO [11],
and increased the perceived exertion after 15 minutes of exercise
[12]. Aerobic exercise of moderate intensity is recommended for at
least 30 minutes a day, at least 5 days a week [13], and it is the key
component in hypertension control and prognostic improvement.
Houston [14] also recommended that b-blockers should be the last
choice for hypertensive patients who are physically active. We
suggest that physicians should monitor a patient’s exercise toler-
ance before and after the initiation of b-blocker treatment.
There are several limitations in the present study. First, it is
a retrospective study analyzing the effects of b-blockers on
a cardiopulmonary exercise test. Second, our sample size was too
small to display more signiﬁcant differences in other exercise
capacity parameters, such as the work rate and exercise duration.
Third, we did not record the duration of antihypertensive treatment
or the hypertension history, because it may inﬂuence the results of
exercise performance. Fourth, we did not distinguish the effects of
selective b-blockers from nonselective ones on exercise perfor-
mance. Further research could focus more speciﬁcally on exam-
ining the differences.
5. Conclusion
In conclusion, b-blockers and other antihypertensives can ach-
ieve similar effects in lowering BP, but b-blockers limit exercise
performance, as measured by the HR, SBP, and _VO2%, during peak
exercise. When choosing antihypertensive drugs, wewould suggest
agents that do not interfere with exercise capacity.
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